Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7678597rdf:typepubmed:Citationlld:pubmed
pubmed-article:7678597lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:7678597lifeskim:mentionsumls-concept:C0206116lld:lifeskim
pubmed-article:7678597lifeskim:mentionsumls-concept:C0021755lld:lifeskim
pubmed-article:7678597lifeskim:mentionsumls-concept:C0164209lld:lifeskim
pubmed-article:7678597lifeskim:mentionsumls-concept:C0038585lld:lifeskim
pubmed-article:7678597lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:7678597lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:7678597lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:7678597lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:7678597lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:7678597pubmed:issue1lld:pubmed
pubmed-article:7678597pubmed:dateCreated1993-2-19lld:pubmed
pubmed-article:7678597pubmed:abstractTextSubstance P (SP) is a central and peripheral neurotransmitter which has been found in multiple sclerosis plaques. SP stimulates peripheral immune cells and may play a role in some chronic inflammatory diseases. Human peripheral monocyte/macrophages have been shown to produce the inflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF alpha) in response to SP. Therefore, in this study we examined rat brain microglia for the presence of SP receptors and production of IL-1 and TNF alpha in response to SP. Microglia had 4900 +/- 950 (mean +/- SE) receptors per cell fitting a two-site model. Four percent of these were high-affinity receptors with a Kd of 8.2 x 10(-8) M +/- 3.6 x 10(-8) M (mean +/- SE), and 96% of them were low-affinity receptors with a Kd of 2.1 x 10(-6) M +/- 5.2 x 10(-7) M (mean +/- SE). Competitive studies with CP 96,345 and other SP analogs demonstrate these to be non-classical NK-1 receptors. SP alone did not stimulate IL-1 or TNF alpha production. However, SP in synergy with lipopolysaccharide (LPS) quadrupled IL-1 production compared to LPS alone, but did not affect TNF alpha production. These results have implications for certain inflammatory conditions in the central nervous system.lld:pubmed
pubmed-article:7678597pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678597pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678597pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678597pubmed:languageenglld:pubmed
pubmed-article:7678597pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678597pubmed:citationSubsetIMlld:pubmed
pubmed-article:7678597pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678597pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678597pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678597pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678597pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678597pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7678597pubmed:statusMEDLINElld:pubmed
pubmed-article:7678597pubmed:monthJanlld:pubmed
pubmed-article:7678597pubmed:issn0165-5728lld:pubmed
pubmed-article:7678597pubmed:authorpubmed-author:MerrillJ EJElld:pubmed
pubmed-article:7678597pubmed:authorpubmed-author:ShanahanFFlld:pubmed
pubmed-article:7678597pubmed:authorpubmed-author:MartinF CFClld:pubmed
pubmed-article:7678597pubmed:authorpubmed-author:GornbeinJ AJAlld:pubmed
pubmed-article:7678597pubmed:authorpubmed-author:AntonP APAlld:pubmed
pubmed-article:7678597pubmed:issnTypePrintlld:pubmed
pubmed-article:7678597pubmed:volume42lld:pubmed
pubmed-article:7678597pubmed:ownerNLMlld:pubmed
pubmed-article:7678597pubmed:authorsCompleteYlld:pubmed
pubmed-article:7678597pubmed:pagination53-60lld:pubmed
pubmed-article:7678597pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7678597pubmed:meshHeadingpubmed-meshheading:7678597-...lld:pubmed
pubmed-article:7678597pubmed:meshHeadingpubmed-meshheading:7678597-...lld:pubmed
pubmed-article:7678597pubmed:meshHeadingpubmed-meshheading:7678597-...lld:pubmed
pubmed-article:7678597pubmed:meshHeadingpubmed-meshheading:7678597-...lld:pubmed
pubmed-article:7678597pubmed:meshHeadingpubmed-meshheading:7678597-...lld:pubmed
pubmed-article:7678597pubmed:meshHeadingpubmed-meshheading:7678597-...lld:pubmed
pubmed-article:7678597pubmed:meshHeadingpubmed-meshheading:7678597-...lld:pubmed
pubmed-article:7678597pubmed:meshHeadingpubmed-meshheading:7678597-...lld:pubmed
pubmed-article:7678597pubmed:meshHeadingpubmed-meshheading:7678597-...lld:pubmed
pubmed-article:7678597pubmed:meshHeadingpubmed-meshheading:7678597-...lld:pubmed
pubmed-article:7678597pubmed:meshHeadingpubmed-meshheading:7678597-...lld:pubmed
pubmed-article:7678597pubmed:meshHeadingpubmed-meshheading:7678597-...lld:pubmed
pubmed-article:7678597pubmed:year1993lld:pubmed
pubmed-article:7678597pubmed:articleTitleProduction of interleukin-1 by microglia in response to substance P: role for a non-classical NK-1 receptor.lld:pubmed
pubmed-article:7678597pubmed:affiliationDepartment of Neurology, School of Medicine, University of California, Los Angeles 90024.lld:pubmed
pubmed-article:7678597pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7678597pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7678597pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7678597lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7678597lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7678597lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7678597lld:pubmed